Cytonics Completes $4.8 Million Gross-Proceeds Financing Campaign

Clinical-stage biotechnology company adds approximately 900 new investors, expands its cap table to approximately 8,000, and brings total capital raised to $47 million

JUPITER, Fla., Sept. 9, 2026 /PRNewswire/ -- Cytonics Corporation, a clinical-stage biotechnology company developing A2M-based therapies for osteoarthritis and other protease-driven diseases, today announced the completion of its latest financing campaign. The company generated $4.8 million in gross proceeds across approximately 1,500 investments, including approximately 900 new investors. Thirty-five percent of its pre-raise shareholder base invested again during the round. Cytonics now has approximately 8,000 investors on its cap table and has raised $47 million to date, including $27 million through Regulation A and Regulation Crowdfunding offerings.

The financing is expected to support continued development of CYT-108, Cytonics' investigational engineered alpha-2-macroglobulin, or A2M, biologic. CYT-108 is designed to inhibit multiple classes of destructive proteases involved in cartilage degradation. The company has completed a first-in-human Phase 1 study and is advancing the regulatory, manufacturing, and clinical planning required for a Phase 1b/2a study in knee osteoarthritis.

"Every dollar in this campaign came from people who made a deliberate decision that this science deserves to advance," said Joey Bose, President and Chief Executive Officer of Cytonics. "Biotechnology is usually financed by a small circle of institutions. We have built Cytonics differently. This financing gives us additional resources to execute the next stage of the program while preserving the independent, shareholder-driven model that brought us here."

Cytonics has received more than $4.32 million in non-binding indications of interest for a potential future financing campaign. The company expects to consider a new campaign in the coming months, after additional regulatory milestones and key efficacy data become available and before the planned Phase 1b/2a study. The timing, structure, terms, and launch of any future offering have not been finalized.

Individuals who wish to receive information if and when a future campaign is launched may submit a non-binding reservation at invest.cytonics.com.

About Cytonics Corporation

Cytonics Corporation is a clinical-stage biotechnology company developing therapies designed to address destructive protease activity implicated in osteoarthritis and other diseases. Its lead program, CYT-108, is an investigational engineered A2M-based biologic designed to inhibit multiple proteases involved in cartilage degradation. Cytonics' A2M platform originated with APIC, its first-generation physician-administered autologous technology for concentrating naturally occurring A2M from a patient's own blood. Learn more at cytonics.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the use of financing proceeds; the development, regulatory, manufacturing, and clinical plans for CYT-108; the timing and design of a potential Phase 1b/2a study; the potential applicability of Cytonics' technology to melanoma or veterinary uses; activities in the United Arab Emirates; and the timing or launch of any future financing campaign. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Cytonics undertakes no obligation to update these statements except as required by law.

Reservation Notice

No offer to buy or sell securities is being made. No money is being solicited, and if sent, it will be returned. Reservations are non-binding indications of interest and involve no obligation or commitment of any kind. Any future offering will be made only through the appropriate intermediary after the required offering statement has been filed, and prospective investors must review the applicable offering materials before investing.

SOURCE Cytonics Corporation